questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Protéines membranaires
Récepteurs de surface cellulaire
Récepteurs immunologiques
Intégrines
Intégrines alpha
Intégrine alpha2
Intégrine alpha2 : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Intégrine alpha2 : Questions médicales les plus fréquentes",
"headline": "Intégrine alpha2 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Intégrine alpha2 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-17",
"dateModified": "2025-04-13",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Intégrine alpha2"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Intégrines alpha",
"url": "https://questionsmedicales.fr/mesh/D039001",
"about": {
"@type": "MedicalCondition",
"name": "Intégrines alpha",
"code": {
"@type": "MedicalCode",
"code": "D039001",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.543.750.705.408.100"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Intégrine alpha2",
"alternateName": "Integrin alpha2",
"code": {
"@type": "MedicalCode",
"code": "D039421",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Evgenia Sitnikova",
"url": "https://questionsmedicales.fr/author/Evgenia%20Sitnikova",
"affiliation": {
"@type": "Organization",
"name": "Institute of the Higher Nervous Activity and Neurophysiology of Russian Academy of Sciences, Butlerova Str., 5A, Moscow 117485, Russia."
}
},
{
"@type": "Person",
"name": "Elizaveta Rutskova",
"url": "https://questionsmedicales.fr/author/Elizaveta%20Rutskova",
"affiliation": {
"@type": "Organization",
"name": "Institute of the Higher Nervous Activity and Neurophysiology of Russian Academy of Sciences, Butlerova Str., 5A, Moscow 117485, Russia."
}
},
{
"@type": "Person",
"name": "Jia Liu",
"url": "https://questionsmedicales.fr/author/Jia%20Liu",
"affiliation": {
"@type": "Organization",
"name": "Shenzhen Jiake Biotechnology, Shenzhen, China."
}
},
{
"@type": "Person",
"name": "Michael Bachmann",
"url": "https://questionsmedicales.fr/author/Michael%20Bachmann",
"affiliation": {
"@type": "Organization",
"name": "Department of Cell Physiology and Metabolism, University of Geneva, Centre Médical Universitaire, Rue Michel-Servet 1, 1211 Geneva 4, Switzerland."
}
},
{
"@type": "Person",
"name": "Vesa P Hytönen",
"url": "https://questionsmedicales.fr/author/Vesa%20P%20Hyt%C3%B6nen",
"affiliation": {
"@type": "Organization",
"name": "Faculty of Medicine and Health Technology, Tampere University, Arvo Ylpön katu 34, FI-33520 Tampere, Finland."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Financial sector development and energy poverty: empirical evidence from developing countries.",
"datePublished": "2023-01-30",
"url": "https://questionsmedicales.fr/article/36715805",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11356-023-25585-6"
}
},
{
"@type": "ScholarlyArticle",
"name": "Asthma in developing countries in the Asia-Pacific Region (APR).",
"datePublished": "2023-09-13",
"url": "https://questionsmedicales.fr/article/37702387",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/resp.14590"
}
},
{
"@type": "ScholarlyArticle",
"name": "Use and misuse of ultrasound in obstetrics with reference to developing countries.",
"datePublished": "2022-10-28",
"url": "https://questionsmedicales.fr/article/36302110",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1515/jpm-2022-0438"
}
},
{
"@type": "ScholarlyArticle",
"name": "Treatment results of carotid artery stenting in a developing country.",
"datePublished": "2023-04-14",
"url": "https://questionsmedicales.fr/article/37075437",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1590/1806-9282.20220525"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cranioplasty Outcomes from a Tertiary Hospital in a Developing Country.",
"datePublished": "2024-05-01",
"url": "https://questionsmedicales.fr/article/39028166",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.4103/aam.aam_53_23"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines membranaires",
"item": "https://questionsmedicales.fr/mesh/D008565"
},
{
"@type": "ListItem",
"position": 5,
"name": "Récepteurs de surface cellulaire",
"item": "https://questionsmedicales.fr/mesh/D011956"
},
{
"@type": "ListItem",
"position": 6,
"name": "Récepteurs immunologiques",
"item": "https://questionsmedicales.fr/mesh/D011971"
},
{
"@type": "ListItem",
"position": 7,
"name": "Intégrines",
"item": "https://questionsmedicales.fr/mesh/D016023"
},
{
"@type": "ListItem",
"position": 8,
"name": "Intégrines alpha",
"item": "https://questionsmedicales.fr/mesh/D039001"
},
{
"@type": "ListItem",
"position": 9,
"name": "Intégrine alpha2",
"item": "https://questionsmedicales.fr/mesh/D039421"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Intégrine alpha2 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Intégrine alpha2",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-15",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Intégrine alpha2",
"description": "Comment diagnostiquer une anomalie d'intégrine alpha2 ?\nQuels examens sont recommandés pour l'intégrine alpha2 ?\nQuels marqueurs biologiques sont associés à l'intégrine alpha2 ?\nL'imagerie est-elle utile pour l'intégrine alpha2 ?\nPeut-on détecter l'intégrine alpha2 dans le sang ?",
"url": "https://questionsmedicales.fr/mesh/D039421?mesh_terms=Developing+Countries&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Intégrine alpha2",
"description": "Quels symptômes sont liés à une déficience d'intégrine alpha2 ?\nL'intégrine alpha2 affecte-t-elle la peau ?\nY a-t-il des symptômes systémiques associés ?\nComment l'intégrine alpha2 influence-t-elle l'inflammation ?\nDes douleurs articulaires peuvent-elles être liées à l'intégrine alpha2 ?",
"url": "https://questionsmedicales.fr/mesh/D039421?mesh_terms=Developing+Countries&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Intégrine alpha2",
"description": "Comment prévenir les troubles liés à l'intégrine alpha2 ?\nY a-t-il des tests de dépistage recommandés ?\nL'exercice physique joue-t-il un rôle préventif ?\nLes vaccinations sont-elles importantes ?\nLe stress a-t-il un impact sur l'intégrine alpha2 ?",
"url": "https://questionsmedicales.fr/mesh/D039421?mesh_terms=Developing+Countries&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Intégrine alpha2",
"description": "Quels traitements sont disponibles pour les anomalies d'intégrine alpha2 ?\nLa thérapie génique est-elle une option ?\nDes médicaments spécifiques ciblent-ils l'intégrine alpha2 ?\nComment la physiothérapie aide-t-elle ?\nLes traitements sont-ils personnalisés ?",
"url": "https://questionsmedicales.fr/mesh/D039421?mesh_terms=Developing+Countries&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Intégrine alpha2",
"description": "Quelles complications peuvent survenir avec une anomalie d'intégrine alpha2 ?\nL'intégrine alpha2 est-elle liée à des maladies auto-immunes ?\nDes complications cardiovasculaires sont-elles possibles ?\nComment les complications affectent-elles la qualité de vie ?\nLes complications sont-elles réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D039421?mesh_terms=Developing+Countries&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Intégrine alpha2",
"description": "Quels sont les facteurs de risque pour les troubles d'intégrine alpha2 ?\nL'âge influence-t-il le risque d'anomalies ?\nLe mode de vie affecte-t-il le risque ?\nLes infections antérieures sont-elles un facteur de risque ?\nLe tabagisme influence-t-il le risque ?",
"url": "https://questionsmedicales.fr/mesh/D039421?mesh_terms=Developing+Countries&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une anomalie d'intégrine alpha2 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses de sang peuvent être utilisés pour diagnostiquer des anomalies."
}
},
{
"@type": "Question",
"name": "Quels examens sont recommandés pour l'intégrine alpha2 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des biopsies et des tests d'adhésion cellulaire peuvent être effectués pour évaluer l'intégrine alpha2."
}
},
{
"@type": "Question",
"name": "Quels marqueurs biologiques sont associés à l'intégrine alpha2 ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les marqueurs comme les cytokines et les facteurs de croissance peuvent être évalués."
}
},
{
"@type": "Question",
"name": "L'imagerie est-elle utile pour l'intégrine alpha2 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie n'est pas directement utilisée, mais peut aider à évaluer les tissus affectés."
}
},
{
"@type": "Question",
"name": "Peut-on détecter l'intégrine alpha2 dans le sang ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des tests sanguins peuvent mesurer les niveaux d'intégrine alpha2 circulante."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une déficience d'intégrine alpha2 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des problèmes de cicatrisation et des troubles immunitaires."
}
},
{
"@type": "Question",
"name": "L'intégrine alpha2 affecte-t-elle la peau ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une déficience peut entraîner des lésions cutanées et une mauvaise cicatrisation."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes systémiques associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes systémiques comme la fatigue et des infections récurrentes peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment l'intégrine alpha2 influence-t-elle l'inflammation ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle régule l'inflammation, et une anomalie peut entraîner une inflammation excessive."
}
},
{
"@type": "Question",
"name": "Des douleurs articulaires peuvent-elles être liées à l'intégrine alpha2 ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des douleurs articulaires peuvent survenir en raison de l'inflammation associée."
}
},
{
"@type": "Question",
"name": "Comment prévenir les troubles liés à l'intégrine alpha2 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et un mode de vie sain peuvent aider à prévenir les troubles."
}
},
{
"@type": "Question",
"name": "Y a-t-il des tests de dépistage recommandés ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques peuvent être recommandés pour les personnes à risque familial."
}
},
{
"@type": "Question",
"name": "L'exercice physique joue-t-il un rôle préventif ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut améliorer la santé cellulaire et réduire les risques."
}
},
{
"@type": "Question",
"name": "Les vaccinations sont-elles importantes ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les vaccinations peuvent prévenir les infections qui aggravent les troubles immunitaires."
}
},
{
"@type": "Question",
"name": "Le stress a-t-il un impact sur l'intégrine alpha2 ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress peut affecter la fonction immunitaire et l'expression de l'intégrine alpha2."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les anomalies d'intégrine alpha2 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des thérapies immunomodulatrices et des soins de soutien."
}
},
{
"@type": "Question",
"name": "La thérapie génique est-elle une option ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la thérapie génique est explorée pour corriger les anomalies d'intégrine alpha2."
}
},
{
"@type": "Question",
"name": "Des médicaments spécifiques ciblent-ils l'intégrine alpha2 ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des inhibiteurs de l'intégrine alpha2 sont en développement pour traiter certaines maladies."
}
},
{
"@type": "Question",
"name": "Comment la physiothérapie aide-t-elle ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La physiothérapie peut améliorer la fonction et réduire la douleur associée aux troubles."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent être adaptés en fonction des besoins individuels du patient."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec une anomalie d'intégrine alpha2 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des infections récurrentes et des problèmes de cicatrisation."
}
},
{
"@type": "Question",
"name": "L'intégrine alpha2 est-elle liée à des maladies auto-immunes ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies peuvent augmenter le risque de maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "Des complications cardiovasculaires sont-elles possibles ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles d'adhésion cellulaire peuvent contribuer à des problèmes cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Comment les complications affectent-elles la qualité de vie ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent réduire la qualité de vie en limitant les activités quotidiennes."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les troubles d'intégrine alpha2 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, des maladies auto-immunes et le stress."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque d'anomalies ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque d'anomalies d'intégrine alpha2 peut augmenter avec l'âge."
}
},
{
"@type": "Question",
"name": "Le mode de vie affecte-t-il le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent le risque."
}
},
{
"@type": "Question",
"name": "Les infections antérieures sont-elles un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des infections chroniques peuvent prédisposer à des troubles d'intégrine alpha2."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme peut affecter la fonction immunitaire et augmenter le risque."
}
}
]
}
]
}
This study empirically assesses the significance of financial sector development in determining the energy poverty of developing countries. The study utilizes a sample of 110 developing economies over...
There is growing interest in the epidemiology of asthma in developing countries, especially in the Asia-Pacific Region (APR). A number of reviews have been published in this field, but a comprehensive...
Maternal and neonatal health is one of the main global health challenges. Every day, approximately 800 women and 7,000 newborns die due to complications during pregnancy, delivery, and neonatal period...
The purpose of this study was to investigate the details of minor complications of carotid artery stenting in a developing country....
This was a retrospective, single-center study conducted on the target group consisting of 65 symptomatic patients who underwent carotid artery stenting. We assessed technical success rate, periprocedu...
Minor periprocedural complications occurred in 15 patients. In all, 8 (12.3%) had transient hypotension, 6 (9.2%) had bradycardia, 7 (10.7%) had acute kidney injury, 2 (3.1%) had vasospasm, and 1 (1.5...
The results of the carotid artery stenting procedures performed in a developing country were acceptable....
Decompressive craniectomy (DC) is a surgical procedure to treat refractory increase in intracranial pressure. DC is frequently succeeded by cranioplasty (CP), a reconstructive procedure to protect the...
A single-center retrospective cohort study was performed, including patients who underwent CP after DC between January 2014 and January 2022. Relevant information was collected such as demographics, t...
Most patients were male (78%). The sample median age was 29 years, with pediatric patients, accounting for 36% of the samples. Overall complication rate was 57% and they were seizure/epilepsy in 50% o...
Despite CP being a simple procedure, it has a considerable rate of complications. Therefore, it is important that surgeons possess adequate knowledge about such complications to navigate these challen...
Procedural skills training in a developing country is challenging, but can improve the quality of care for patients with an important regional health problem. A structured, brief, teach-the-teacher-ba...
Phenome-wide association studies (PheWASs), a powerful approach that examines phenotypes associated with a genetic marker, have been used extensively in highly developed countries. Although there may ...
Lupus nephritis (LN) has variable prevalence, severity, and outcomes across the world....
This review compares the outcomes of childhood LN in low- and middle-income countries (LMICs) and high-income countries (HICs) and aims to summarize long-term outcomes of pediatric LN from LMICs....
A systematic literature search, conducted in PubMed, EMBASE, and Cochrane database in the last 30-years from January 1992, published in the English language, identified 113 studies including 52 from l...
Cohort studies or randomized controlled trials, of patients ≤ 18 years of age (or where such data can be separately extracted), with > 10 patients with clinically or histologically diagnosed LN and ou...
Patients ≤ 18 years of age with clinically or histologically diagnosed LN; effect of an intervention was not measured....
Two authors independently extracted data. We separately analyzed studies from developed countries (high income countries; HIC) and developing countries (LMICs). Middle-income countries were further cl...
Kidney remission was similar across MICs and HICs with 1-year pooled complete remission rates of 59% (95% CI 51-67%); one third of patients had kidney flares. The pooled 5-year survival free of stage ...
The review is limited by heterogenous approach to diagnosis and management that has changed over the period spanning the review. World Bank classification based on income might not correlate with the ...
Challenges in LMICs include limited access to pediatric nephrology care, dialysis, increased risk of infection-induced mortality, lack of frequent monitoring, and non-compliance due to cost of therapy...
PROSPERO 2022 number: CRD42022359002, available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022359002....
To evaluate the process of diagnosing patients with malignant pleural mesothelioma (MPM) at a tertiary care hospital....
This was a retrospective study involving patients referred to a tertiary-care cancer center in Brazil between 2009 and 2020. The diagnostic process was divided into four steps: onset of symptoms, refe...
During the study period, 66 patients (mean age = 64 years) were diagnosed with MPM and underwent treatment. Only 27 (41%) of the patients had knowledge of prior exposure to asbestos. The median number...
The unfamiliarity of health professionals with MPM and the patient's lack of knowledge of prior asbestos exposure were the major factors to cause a long time interval between the onset of symptoms and...
The effective and efficient management of financial systems and resources fosters a socioeconomic climate conducive to technological and innovative advancement, thereby fostering long-term economic gr...